Home Stocks CRBP Corbus Pharmaceuticals Holding (NASDAQ: CRBP) Healthcare · Biotechnology
$2.75 −0.27 (−8.80%)
Last close · Nov 18, 2026 · NASDAQ USD
The Quantellect read. CRBP fell 8.80% in the Nov 18 session to $2.75, which is 77.4% below its 52-week high of $12.15. Six active firms cover the stock as of Nov 19, 2026; six active firms with targets average $37.50 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Momentum Neutral RSI (14) 41.3 (overbought above 70, oversold below 30)
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open $2.96 Nov 18, 2026 session
Previous close $3.01 Nov 17, 2026 close
Day range $2.62 – $3.00 Nov 18, 2026 session
52-week range $2.75 – $12.15 Through Nov 18, 2026
Volume 632.70K Nov 18, 2026 session
Average volume (30 calendar days, 0 sessions) — Through Nov 18, 2026
Market cap $69.86M
P/E (TTM) negative earnings —
Forward P/E —
EPS (TTM) −$6.04
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) 2.85
Price history CRBP · nasdaq · USD
Last completed session: Nov 18, 2026
Split-adjusted · volume in shares
November 2026 · 13 completed sessions Date Open High Low Close Change Volume Nov 18 2.96 3.0029 2.62 2.745 −0.265−8.803987% 630,362 Open 2.96 High 3.0029 Low 2.62 Nov 17 3.29 3.34 2.9525 3.01 −0.365−10.814815% 570,863 Open 3.29 High 3.34 Low 2.9525 Nov 16 3.41 3.62 3.00 3.375 −0.015−0.442478% 953,696 Open 3.41 High 3.62 Low 3.00 Nov 13 3.38 3.53 3.27 3.39 −0.02−0.58651% 575,119 Open 3.38 High 3.53 Low 3.27 Nov 12 4.00 4.01 3.2301 3.41 −0.59−14.75% 1,050,996 Open 4.00 High 4.01 Low 3.2301 Nov 11 4.04 4.20 3.80 4.00 +0.07+1.78117% 672,732 Open 4.04 High 4.20 Low 3.80 Nov 10 3.39 3.98 3.21 3.93 +0.41+11.647727% 645,629 Open 3.39 High 3.98 Low 3.21 Nov 9 3.11 3.745 3.11 3.52 +0.45+14.65798% 1,247,576 Open 3.11 High 3.745 Low 3.11 Nov 6 2.93 3.125 2.91 3.07 +0.21+7.342657% 685,228 Open 2.93 High 3.125 Low 2.91 Nov 5 3.57 3.57 2.81 2.86 −0.71−19.887955% 1,356,435 Open 3.57 High 3.57 Low 2.81 Nov 4 3.97 4.0992 3.57 3.57 −0.30−7.751938% 2,012,725 Open 3.97 High 4.0992 Low 3.57 Nov 3 3.92 4.11 3.73 3.87 −0.045−1.149425% 4,367,646 Open 3.92 High 4.11 Low 3.73 Nov 2 4.21 4.23 3.895 3.915 −0.305−7.227488% 674,178 Open 4.21 High 4.23 Low 3.895
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
Quantellect signals — · Quantellect signals not available
Industry comparison — · Industry comparison not available
Upcoming events — · Upcoming events not available
Analyst consensus Buy
0 Strong Buy
6 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 6 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $30.00
Average $37.50
High $48.00
As of Nov 19, 2026 across 6 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −6.00 −4.00 −2.00 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$1.27 −$1.81 —
Q2 2026 — −$1.81 —
Q1 2026 — −$1.23 —
Annual 2025 — −$5.90 —
Q3 2025 — −$1.90 —
Q2 2025 — −$1.44 —
Q1 2025 — −$1.39 —
Annual 2024 −$1.26 −$3.68 —
Smart-money activity In the last 60 days: 1 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Oct 29, 2026 Insider sell Cormorant Asset Management, LP / Cormorant Global Healthcare Master Fund, LP / Chen Bihua Sell $1.7M Form 4 Aug 11, 2026 Insider buy Saxena Nishant C Buy $25.0K Form 4 Aug 7, 2026 Insider sell Cohen Yuval Sell $171.4K Form 4 Aug 7, 2026 Insider sell Moran Sean F. Sell $121.0K Form 4 Jun 10, 2026 Insider sell Kung Winston Sell $16.0K Form 4 Jun 10, 2026 Insider sell Jenkins John Kenneth Sell $38.0K Form 4 Jun 10, 2026 Insider sell Altmeyer Anne Sell $19.1K Form 4 Jun 3, 2026 Insider buy Saxena Nishant C Buy $68.2K Form 4 Jun 2, 2026 Insider buy Saxena Nishant C Buy $33.0K Form 4 All smart-money activity →
News and press releases News and press releases are not available.
All CRBP news → Company profile Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
CEO Dr. Yuval Cohen Ph.D.
Headquarters Norwood, MA, United States
Employees 36
IPO date Nov 11, 2014
Sector Healthcare
Industry Biotechnology Q Score — · Q Score not available
Quantellect signals — · Quantellect signals not available
Upcoming events — · Upcoming events not available
Analyst consensus Buy
0 Strong Buy
6 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 6 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $30.00
Average $37.50
High $48.00
As of Nov 19, 2026 across 6 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −6.00 −4.00 −2.00 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$1.27 −$1.81 —
Q2 2026 — −$1.81 —
Q1 2026 — −$1.23 —
Annual 2025 — −$5.90 —
Q3 2025 — −$1.90 —
Q2 2025 — −$1.44 —
Q1 2025 — −$1.39 —
Annual 2024 −$1.26 −$3.68 —
Company profile Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
CEO Dr. Yuval Cohen Ph.D.
Headquarters Norwood, MA, United States
Employees 36
IPO date Nov 11, 2014
Sector Healthcare
Industry Biotechnology